EWING, N.J., April 6, 2015 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that data for CPX-351, its lead product candidate, will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, PA on April 18-22, 2015.
These presentations describe the effects of combining CPX-351 with existing chemotherapies used to treat AML and other blood cancers as well as, for the first time, with novel molecularly targeted agents that have demonstrated activity in clinical trials. In both cases, the combined agents complemented each other’s anti-leukemic properties, resulting in an enhanced overall effect.
“We are very encouraged by the CPX-351 data we are seeing, both as a stand-alone product and now in combination with other treatment approaches,” said Lawrence Mayer, Ph.D., President and Chief Scientific Officer at Celator. “As we await the clinical data from the CPX-351 Phase 3 trial, we remain committed to exploring the expanded potential of CPX-351 as a foundation of care upon which additional agents can be added to further improve the outcomes of patients with AML as well as other blood cancers.”
Abstracts submitted and selected for poster presentation are:
Presentation Title: | Detection of Ara-CTP following exposure to CPX-351 and potentiation of action by fludarabine in leukemia cell lines using a bioluminescent bacterial biosensor |
Date: | Monday, April 20, 2015, 1:00 p.m.-5:00 p.m. |
Session Category: | Experimental and Molecular Therapeutics |
Session Title: | Combination Chemotherapy 1 |
Location: | Poster Section 27 |
Abstract Number: | 2526 |
Presentation Title: | CPX-351 (cytarabine:daunorubicin liposome for injection) anti-leukemia activity is potentiated by Chk1 inhibition |
Date: | Tuesday, April 21, 2015, 8:00 a.m.-12:00 p.m. |
Session Category: | Experimental and Molecular Therapeutics |
Session Title: | Combination Chemotherapy 2 |
Location: | Poster Section 27 |
Abstract Number: | 3479 |
The posters will be available on Celator’s website (www.celatorpharma.com) at the conclusion of the AACR meeting.
About Celator Pharmaceuticals, Inc.
Celator Pharmaceuticals, Inc., with locations in Ewing, N.J., and Vancouver, B.C., is a clinical stage biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator’s proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensure its exposure to the tumor. Celator’s pipeline includes lead product, CPX-351 (a liposomal formulation of cytarabine:daunorubicin) for the treatment of acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine) for the treatment of colorectal cancer; a preclinical stage product candidate, CPX-8 (a hydrophobic docetaxel prodrug nanoparticle formulation), being studied by the National Cancer Institute’s Nanotechnology Characterization Laboratory. The company is advancing the CombiPlex platform and broadening its application to include molecularly targeted therapies and epigenetic modulators.
For more information, please visit Celator’s website at www.celatorpharma.com. Information on ongoing trials is available at www.clinicaltrials.gov.
Forward-Looking Statements:
To the extent that statements contained in this press release are not descriptions of historical facts regarding Celator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “anticipate,” “estimate,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the safety, efficacy and therapeutic potential of CPX-351, the availability of data from clinical studies and our expectations regarding our research and development programs, expanding our pipeline and advancing our CombiPlex platform. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, working capital performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical studies, enrollment in clinical studies, availability of data from ongoing clinical studies and other matters that could affect the commercial potential of our drug candidates. Celator undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Celator in general, see Celator’s Form 10-K for the year ended December 31, 2014 and other filings by Celator with the U.S. Securities and Exchange Commission.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/celator-pharmaceuticals-to-present-data-at-the-american-association-for-cancer-research-annual-meeting-300061094.html
SOURCE Celator Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.
